Aspyrian, Goodwin team up in antibody-drug-conjugate venture
Aspyrian Therapeutics and Goodwin Biotechnology said on Tuesday that they will collaborate on the development and scaling processes of Aspyrian's new antibody drug conjugate (ADC) platform. Aspyrian's platform is a near-infrared photo-immunotherapy technological platform that uses a laser of visible light to eliminate tumors and leave surrounding healthy tissue unharmed. Read More »
Alerts Sign-up